New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes

Exceptional Innovationon Diabetes

Innovation on Diabetes +

  • Efficacy comparable to reference antidiabetics (metformin, pioglitazone)
  • Glucose regulatory activity by insulin sensitization
  • No detectable toxicity in animal models
  • Worldwide patent protection
Additional Information

Additional Information

  • Positive cardiovascular effects by reducing systolic arterial pressure.
  • Significant reduction of obesity.
  • Proved regulating effect in diabetes, hypertension, dyslipidemia, overweight, hepatic steatosis and NASH.
  • Simple method of synthesis with high yield and purity.
  • 3 compounds in pre-clinical development.

Company

Biotechnology company supported by a prestigious multidisciplinary team, CROs, and universities operating from several continents.

More information

Scientific Development

Family of molecules with therapeutic potential for diabetes, hypertension, dyslipidemia, overweight, hepatic steatosis and NASH.

More information

Patents

All our compounds are protected by international patent, with national phases granted in the main countries of the world.

More information

New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes